sulfasalazine has been researched along with Adenomatous Polyps in 1 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Adenomatous Polyps: Benign neoplasms derived from glandular epithelium. (From Stedman, 25th ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| " To directly evaluate the ability of 5-ASA to suppress intestinal tumors, we studied several formulations of 5-ASA (free acid, sulfasalazine, and Pentasa) at multiple oral dosage levels [500, 2400, 4800, and 9600 parts/million (ppm)] in the adenomatous polyposis coli (Apc) mouse model of multiple intestinal neoplasia (Min)." | 1.30 | Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse. ( Gendler, SJ; Hirsch, RE; Leighton, JA; Morrow, JD; Ritland, SR; Weaver, AL, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ritland, SR | 1 |
| Leighton, JA | 1 |
| Hirsch, RE | 1 |
| Morrow, JD | 1 |
| Weaver, AL | 1 |
| Gendler, SJ | 1 |
1 other study available for sulfasalazine and Adenomatous Polyps
| Article | Year |
|---|---|
Evaluation of 5-aminosalicylic acid (5-ASA) for cancer chemoprevention: lack of efficacy against nascent adenomatous polyps in the Apc(Min) mouse.
Topics: Adenomatous Polyps; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Chemo | 1999 |